Asmanex Twisthaler approved for pediatric asthma
The FDA has approved Asmanex Twisthaler (mometasone furoate inhalation powder, from Schering-Plough) 110 mcg for the maintenance treatment of asthma as a preventive therapy in patients 4-11 years of age. This approval is supported by a pediatric, placebo-controlled trial involving 296 patients that showed significant improvement in forced expiratory volume in one second (FEV1) in the Asmanex-treated group compared to placebo.
Asmanex Twisthaler 220mcg is already available for the maintenance treatment of asthma as prophylactic therapy in patients ≥12 years of age.
For more information call (800) 526-4099 or visit www.asmanex.com.